To improve the staging accuracy of patients with moderate to advanced cervical cancer and monitor the treatment effect by low-cost and noninvasive methods at the same time, the study combined MRI and serum HE4, TSGF, and CD105 in the application as follows. This evidence concerns the gene ENG and cervical cancer.